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Abstract
FGF1 is a signal peptide-less nonclassically released growth factor that is involved in angiogenesis, tissue repair,
inflammation, and carcinogenesis. The effects of nonclassical FGF export in vivo are not sufficiently studied. We produced
transgenic mice expressing FGF1 in endothelial cells (EC), which allowed the detection of FGF1 export to the vasculature,
and studied the efficiency of postischemic kidney repair in these animals. Although FGF1 transgenic mice had a normal
phenotype with unperturbed kidney structure, they showed a severely inhibited kidney repair after unilateral ischemia/
reperfusion. This was manifested by a strong decrease of postischemic kidney size and weight, whereas the undamaged
contralateral kidney exhibited an enhanced compensatory size increase. In addition, the postischemic kidneys of transgenic
mice were characterized by hyperplasia of interstitial cells, paucity of epithelial tubular structures, increase of the areas
occupied by connective tissue, and neutrophil and macrophage infiltration. The continuous treatment of transgenic mice
with the cell membrane stabilizer, taurine, inhibited nonclassical FGF1 export and significantly rescued postischemic kidney
repair. It was also found that similar to EC, the transgenic expression of FGF1 in monocytes and macrophages suppresses
kidney repair. We suggest that nonclassical export may be used as a target for the treatment of pathologies involving signal
peptide-less FGFs.
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Introduction
Members of the fibroblast growth factor (FGF) family play
critical roles in developmental and pathological processes
[1,2,3,4]. Most FGFs signal through specific transmembrane
receptors (FGFR), and thus require secretion for their biological
activities [1,2,3,4]. The majority of FGFs have a cleavable
hydrophobic N-terminal peptide in their structure that allows
their release through the classical secretion pathway, which
involves the endoplasmic reticulum and Golgi apparatus. In
contrast, two most widely expressed members of the family, FGF1
and FGF2, are devoid of signal peptide and thus are released
through unconventional secretion pathways [5,6,7,8]. FGF1 and
FGF2 are expressed in epithelial and endothelial cells, and
mononuclear leukocytes in kidneys under normal and pathological
conditions [9,10,11,12]. FGF1 has potent effects in embryonic
kidney culture, regulating ureteric bud branching [13] and
nephron progenitor cell maintenance [14]. Recombinant FGF1
and FGF2 improve wound healing [15], post-ischemic heart repair
[16,17,18,19], and formation of collaterals after hindlimb ischemia
[20]. The knockdown of FGFR2 exacerbated [21] and delivery of
recombinant FGF2 attenuated [22] postischemic kidney damage.
However the latter experiments were limited to first 4 days after
ischemia apparently due to insufficient stability of recombinant
FGFs in the organism [23].
We propose to use conditional transgenic expression of FGF1 to
elucidate long-term effects of this signaling ligand on kidney injury.
To that end, we created transgenic mice with conditional FGF1
expression in endothelial cells (EC) abundantly present in kidneys.
The production of FGF1 in EC directly facing the bloodstream
facilitated the assessment of its release. Another advantage of our
in vivo model was that despite permanent FGF1 expression in EC,
transgenic animals exhibited a normal phenotype, including
unperturbed kidney structure; therefore, we were able to
specifically focus on FGF-dependent events caused by ischemia
and postischemic stress. We found that transgenic expression of
FGF1 in EC resulted in the irreversible loss of epithelial tubular
structures and massive fibrosis in the postischemic kidney.
Importantly, these effects were suppressed by taurine, which
inhibits nonclassical FGF1 export in vitro [24] and also in vivo as
we found in the present study. These data demonstrate that
transgenic expression of nonclassically released FGF is compatible
with normal development and morphology of kidneys, but it
suppresses postischemic kidney repair. In addition, they suggest
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36485that targeting nonclassical FGF export may be used for the
treatment of pathological conditions caused by naturally occurring
upregulation of FGF1 and FGF2 expression [25,26,27].
Materials and Methods
1. Production of Transgenic Mice
To produce transgenic mice, we used FGF1 with a R136K
mutation at the thrombin cleavage site located in the heparin
binding domain of FGF1. R136K FGF1 developed as an agent for
wound repair exhibits normal mitogenic activity [28], and we
demonstrated that similar to wild type FGF1, it is normally
released during cell stress [29]. The use of this mutant prevented
thrombin cleavage of FGF1 and thus assured the efficient
collection of vascular FGF1. R136K mutation was introduced
by PCR-based site-directed mutagenesis in the FGF1pMEXneo
expression construct [5]. The codon encoding arginine 136 (AGA)
was changed to a lysine (AAA) (FGF1R136K). FGF1R136K was
cloned into SalI and EcoRI restriction sites of pcDNA3-HA vector
originating FGF1R136K:HA-pcDNA3. We inserted
FGF1R136K:HA into the HindIII and XbaI restriction sites of
the pTRE-Tight expression vector (Clontech) to obtain the
FGF1R136K:HA-pTRE construct. Pronuclei of fertilized oocytes
of FVB mice (Taconic) were injected with FGF1R136K:HA-
pTRE-Tight DNA. RT-PCR was applied to test the integration of
the transgene in the genome of one-month-old mice produced
from injected oocytes. The following two pairs of primers were
used:
a) 59-CGT GTA CGG TGG GAG GCC-39 and 59- CAA ATG
TGG TAT GGC TGA TT- 39
b) 59-GGC TCA CAG ACA CCA AAT G-39 and 59- CAA
ATG TGG TAT GGC TGA TT- 39
FGF1-positive mice were bred with FVB partners; as a result,
six independent transgenic lines were obtained.
To check the inducibility of FGF1 expression in transgenic
mice, we analyzed cultures of tail fibroblasts. The tail snips from
FGF1-transgenic mice were sterilized with ethanol, the skin was
removed, and snips were digested using 70 units/ml solution of
collagenase (Sigma) in DMEM for 3 h at 37uC. Large cell clumps
were then allowed to sediment at 1 g for 5 min. Dissociated cells
were precipitated by centrifugation at 2000 g, resuspended in
DMEM plus 10% fetal calf serum, and plated on fibronectin-
coated glass coverslips placed in the wells of TC6 plates. One week
later, the cells were transiently transfected using Fugene (Roche)
with the CMVt-rtTA construct (gift of Dr. John Hiscott, McGill
University, Montreal, Canada). One day after rtTA transfection,
the fibroblasts were stimulated with 10 mg/ml doxycycline
(Sigma), incubated for an additional 48 h, fixed with 10%
formalin, and immunofluorescently stained with mouse anti-HA
antibodies (Covance) followed by FITC-conjugated anti-mouse
IgG antibodies (Vector Laboratories), and examined under a
confocal fluorescence microscope. Fibroblasts untransfected with
rtTA or transfected with rtTA but untreated with doxycycline did
not express FGF1:HA. Of the six FGF1 transgenic lines examined,
line F demonstrated the most reproducible rtTA-dependent and
doxycycline inducible expression of FGF1:HA. Mice of this line
were bred with Tg(Tek-rtTA,TRE-lacZ)1425Tpr/J transgenic
mice expressing rtTA under the EC-specific Tek promoter (The
Jackson Laboratory). The double transgenic mice were further
bred for three generations onto the FVB background before using
them in kidney ischemia experiment. The genotype of double
transgenic FGF1/Tek mice was confirmed by RT-PCR using the
above mentioned FGF1 primers and two following combinations
of Tg(Tek-rtTA,TRE-lacZ)1425Tpr/J-specific primers recom-
mended by The Jackson Laboratory:
a) 59-CAA ATG TTG CTT GTC TGG TG-39;5 9-GTC AGT
CGA GTG CAC AGT TT-39;5 9-CGC TGT GGG GCA
TTT TAC TTT AG-39;5 9-CAT GTC CAG ATC GAA
ATC GTC-39.
b) 59-CAA ATG TTG CTT GTC TGG TG-39;5 9-GTC AGT
CGA GTG CAC AGT TT-39;5 9-ATC CTC TGC ATG
GTC AGG TC-39;5 9-CGT GGC CTG ATT CAT TCC-39.
In parallel, we bred FGF1 transgenic mice with the animals
expressing rtTA under the macrophage/monocyte specific c-fms
promoter. The original rtTA/c-fms transgenic mice [30] were
bred onto the FVB background before being mated with FGF1
transgenic animals. The genotype of double transgenic FGF1/c-
fms animals was confirmed by PCR using the aforementioned
FGF1 primers and a pair of rtTA/c-fms primers:
59 – TGA TTG AAG GGT CCA GAC TCA TTC –39 and 59 –
AGT GTA GGC TGC TCT ACA CCA AGC –39
2. Determination of FGF1 Content in the Vasculature
To determine the content of FGF1 in the vasculature, the
mice were sacrificed by isoflurane inhalation and their
cardiovascular system was immediately perfused with 10 ml of
ice-cold PBS containing 10 units/ml heparin (Sigma) in order to
detach FGF1 bound to endothelial cells (EC). The diluted blood
was collected and centrifuged for 10 min at 700 g. The content
of FGF1 in the supernatant was determined using the FGF1
ELISA kit (R&D Systems). To determine the FGF1 content in
the vasculature, we considered that the blood volume in mice
averages 7% of its body weight, and assumed that all the blood
was collected by perfusion.
3. Determination of FGF1 Content in Kidneys
To detect FGF1 expression in kidneys, the mice were sacrificed
by isoflurane inhalation followed by cervical dislocation, and a
50 mg fragment of the kidney was snap frozen in liquid nitrogen,
pulverized, and lyzed in SDS-PAGE loading buffer. Samples were
resolved by 15% SDS-PAGE and immunoblotted using rabbit
anti-FGF1 antibodies.
4. Unilateral Kidney Ischemia Reperfusion Injury
This study has been performed in accordance with the National
Research Council Guide for the Care and Use of Laboratory Animals and
approved by the Institutional Animal Care and Use Committee of
Maine Medical Center (approval ID 0701). Only male animals
were used in all the experiments. Male mice between 2 and
3 months of age were anesthetized using a cocktail of xylazine
(14.5 mg/kg) and ketamine (95 mg/kg), and maintained at a core
temperature of 37uC for the duration of the surgical procedure.
The renal pedicle of the right kidney was clamped for 26 min
using a microaneurysm clamp, during which time the kidney was
retained in the abdominal cavity. Animals in which the kidney
either did not discolor within one min after clamping or return to
normal color within two min after removal of the clamp were
excluded from the experiment. Following release of the clamp, the
kidney was returned to the abdomen and the body wall was
sutured to prevent prolapse. Skin staples were used to close the
wound.
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Isolated kidney tissue was added to 1 ml Trizol (Invitrogen)
on ice, homogenized immediately, and snap frozen. Crude total
RNA was purified from 500 ml of lysate according to the
manufacturer’s instructions, and further purified using the
RNeasy Mini kit (Qiagen) with DNase treatment. One mlo f
Ribolock (Fermentas) was added, and cDNA was generated
from 1 mg of RNA using the qScript cDNA kit (Quanta). For
qPCR, 1 ml of cDNA was used as template in a 25 ml reaction
using iQ SYBR Green SuperMix (BioRad) on a MyiQ real time
detection system (Biorad). Cycling parameters were 95uC for 15
seconds or 55uC for 45 seconds. Primer sequences for mouse
KIM1 (Havcr1) were 59-TCGTGTCACCTATCAGAAGAGC-39
and 59- ACAATACAGACCACTGTCACTC-39, and for the b-
actin housekeeping gene 59- CGTGCGTGACATTAAAGA-
GAAG-39 and 59- TGGATGCCACAGCATTCCATA-39. Each
biological sample was assayed in triplicate. Technical replicates
were averaged and 1/DCT was calculated for each biological
sample. The SEM was determined within each group of
biological replicates, and p values were calculated using the
Student’s t-test.
6. Histology and Immunohistochemistry
After perfusion of the mouse vascular system with ice-cold
heparinized PBS, the postischemic and control contralateral
kidneys were fixed for 24 h in the cold 10% neutral formalin.
The paraffin sections of kidneys were prepared and stained with
hematoxylin and eosin, Trichrome, Sirius Red or periodic acid-
Schiff stain (PAS). For DAB-immunoperoxidase detection of
transgenically expressed FGF1, we used anti-HA monoclonal
antibodies (Covance). To identify EC, macrophages, neutrophils,
and proliferating cells, we used respectively: (i) anti-CD31/
PECAM biotinylated rat antibodies (BD Pharmingen), (ii) F4/80
mouse monoclonal antibodies (Santa Cruz), (iii) rat anti-neutrophil
antibodies (AbD Serotec), and (iv) anti-Ki-67 rabbit antibodies
(Abcam).
7. Image Analysis and Statistics
Kidney tubules were counted on hematoxylin and eosin
stained sections, at magnification 610, in 10 fields per section,
by using MacBiophotonic ImageJ program. Decrease of tubule
density was presented as the ratio (%) of average tubular density
in postischemic kidneys to that in contralateral kidneys. From
four to nine mice per experimental group were studied. Means
and SEM were calculated by using GraphPad software. The
significance of differences between transgenic and wild type
(WT) animals was assessed using Student’s t-test. The same
imaging and statistical analysis programs were used to assess the
portion (%) of kidney section positive for Sirius Red staining
(magnification 640, Sirius Red and hematoxylin staining),
percentage of Ki-67-positive nuclei (magnification 620, im-
munoperoxidase staining, hematoxylin counterstaining), and
percentage of dilated tubules, i.e. those where lumen occupies
more than J of tubule section (magnification 620, hematoxylin
and eosin staining). Increase of tubule dilatation was presented
as the ratio (fold) of the percentage of dilated tubules in the
postischemic kidney to that in the contralateral kidney.
Measurement of glomeruli diameters was performed on
hematoxylin and eosin stained sections at magnification 620,
by using a micrometer stage.
Results
1. FGF1/Tek Transgenic Mice Stably Express FGF1 in EC
and Release it to the Circulation
To assess the effect of EC-derived FGF1 on postischemic kidney
repair, we produced transgenic mice with EC-specific expression
of human FGF1. C-terminal HA tag, which does not interfere with
FGF1 release [24], was used for immunohistochemical FGF1
detection. To ensure cell type specific FGF1 expression, we chose
a Tet-based system. FGF1 was cloned in the pTRE-Tight plasmid
(Clontech) and the resultant construct was injected into fertilized
mouse oocytes. We produced several independent lines of FGF1
transgenic FVB mice. By immunoblotting or immunohistochem-
istry, none were found to express detectable amounts of FGF1:HA
in kidney, muscle, or liver (data not shown). To assess the potential
of rtTA-dependent FGF1 expression in transgenic mice, we
isolated fibroblasts from their tails and transiently transfected them
with rtTA. Immunofluorescence analysis demonstrated that
doxycycline treatment induced FGF1:HA expression in cultured
mouse fibroblasts derived from transgenic mice (data not shown).
We bred pTRE-Tight/FGF1 transgenic mice with Tg(Tek-rtTA,
TRE-lacZ)1425Tpr/J transgenic mice expressing rtTA under the
EC-specific Tek promoter. Double transgenic FGF1/Tek mice
were bred onto the FVB background. Immunoperoxidase staining
demonstrated endothelium-specific expression of FGF1:HA in
kidneys without doxycycline treatment (Figure 1A). Western
immunoblot analysis confirmed the expression of FGF1 in the
kidneys of the FGF1/Tek mice dramatically exceeding endoge-
nous FGF1 level (Figure 1B). Furthermore, FGF1 was detected by
ELISA in the vasculature of FGF1/Tek mice untreated with
doxycycline but not in the control mice (Figure 1C). FGF1/Tek
mice did not display any visible pathology and had normal fertility.
The kidneys of FGF1/Tek animals were indistinguishable from
those of control animals by their macroscopic ad microscopic
morphology. The unexpected stable uninduced EC-specific
expression of FGF1 in FGF1/Tek mice simplified our experiments
by eliminating the need for doxycycline stimulation.
2. Early Postischemic Response in FGF1/Tek and Control
Animals
Two- to three-month-old male FGF1/Tek transgenic mice and
control male FVB mice were subjected to 26 min of transient
ischemia of the right kidney. Day 1 after surgery, the mice were
sacrificed and the level of the mouse ortholog of kidney injury
marker 1 (KIM1), Havcr1, was determined by qRT-PCR. One day
after ischemia, the expression of Havcr1 in FGF1/Tek animals was
higher than in control mice (Figure 2A). Despite the trend of
increased Havcr1 expression in transgenic mice relative to WT,
differences between the two genotypes did not reach p,0.05. PAS
staining of kidney sections demonstrated that 24 h after ischemia,
the postischemic kidneys of both FGF1/Tek and control animals
contained in contrast to contralateral organs epithelial tubules,
filled with PAS-positive protein casts characteristic of acute kidney
injury (Figure 2B). Postischemic kidneys were characterized by an
increase of the percentage of dilated tubules, and this increase was
not significantly different between FGF1/Tek and control animals
(Figure 2C). Ischemia did not result in a significant change of the
diameters of glomeruli in the kidneys of both FGF1/Tek and
control mice (Figure 2D).
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in Size Decrease of Postischemic Kidneys and Loss of
Tubular Structures
Three weeks after unilateral ischemia/reperfusion, postischemic
kidneys of FGF1/Tek animals presented a sharp morphological
contrast to control animals. Indeed, their weight was on average
25% less than in the control mice (Figure 3A,B,C). Hematoxylin-
eosin staining of paraffin sections revealed a failure of kidney
repair in postischemic FGF1/Tek animals. Indeed, three weeks
after surgery, the postischemic kidneys of FGF1/Tek mice
exhibited a paucity of epithelial tubules, combined with hyper-
plasia of interstitial cells (Figure 3D,E). Conversely, the histology of
postischemic kidneys in control WT animals was more similar to
that of contralateral organs: efficient restoration of tubular
structures, and few signs of interstitial hyperplasia. The ratio of
tubule density in postischemic FGF1/Tek mice kidneys to tubule
density in contralateral kidneys (Figure 3E) was sharply lower than
this parameter in WT mice. The postischemic kidneys of FGF1/
Tek animals contained abundant capillaries detected by anti-
PECAM staining (Figure S1). Thus, it is unlikely that the observed
changes were due to deficient angiogenesis.
4. Ischemia Results in Fibrosis of FGF1/Tek Kidneys
Abundance of interstitial cells in postischemic kidneys of FGF1/
Tek mice prompted us to assess fibrosis and cell proliferation in
these organs. Trichrome staining (Figure 4A) revealed a strong
expansion of connective tissue in the cortex and medulla of
postischemic kidneys of FGF1/Tek mice compared to control
animals. Staining with the collagen marker Sirius Red was
increased in the interstitium of postischemic FGF1/Tek kidneys
much stronger than in postischemic kidneys of control mice
(Figure 4B, D). Immunohistochemical staining for Ki-67 a marker
of cell proliferation, revealed numerous proliferating cells in the
hyperplastic interstitium of cortex and medulla of FGF1/Tek
kidneys, while Ki-67-positive cells were rare in postischemic
kidneys of control animals (4C, E).
5. FGF1 Expression in EC Enhances the Invasion of
Macrophages and Neutrophils into the Postischemic
Kidneys
Kidney fibrosis is enhanced by the invasion of macrophages and
neutrophils that serve as sources of various profibrotic growth
factors and cytokines [31,32]. To assess the effect of EC-derived
FGF1 on the invasion of inflammatory cells into the kidneys, we
used immunoperoxidase histochemistry with the antibody F4/80
(marker of macrophages) or an anti-neutrophil antibody. We
found that three weeks after surgery, postischemic FGF1/Tek
kidneys contained large groups of macrophages and neutrophils in
the interstitium, whereas in the postischemic kidneys of control
animals, only individual macrophages and neutrophils were found
(Figure 5). Contralateral kidneys of both FGF1/Tek and control
animals were also largely macrophage- and neutrophil-negative.
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Figure 1. Transgenic FGF1 expression and release in FGF1/Tek mice. A. FGF1 is expressed in kidney EC. Immunoperoxidase staining was
used to detect transgenic FGF1 (anti-HA antibodies) and EC (anti-PECAM antibodies) in the paraffin sections of kidneys obtained from FGF1/Tek mice.
Preparations were counterstained with hematoxylin. Bar –30 m. B. Lysates of kidney tissue obtained from FGF1/Tek and control FVB mice were
resolved by SDS-PAGE and immunoblotted using rabbit anti-FGF1 antibodies and mouse monoclonal anti-ß-actin antibodies (loading control). C.
Transgenically expressed FGF1 is released into the vasculature of FGF1/Tek mice. Seven male FGF1/Tek mice and 7 control WT FVB males were
sacrificed; their vasculatures were perfused with cold heparinized PBS and the content of FGF1 (ng/ml blood) was determined using an FGF1 ELISA kit
from R&D.
doi:10.1371/journal.pone.0036485.g001
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Several pharmacological agents have been used with variable
success to treat kidney ischemia and fibrosis [33], i.e. antioxidants,
NO inhibitors, erythropoietin, adenosine, and others [33]. One of
the agents with a beneficial effect on postischemic renal recovery is
the sulfur-containing non-essential amino acid, taurine [34].
In addition to its anti-oxidant properties, taurine acts as a
membrane stabilizer [34]. Because FGF1 is an acidic phospholip-
id-binding protein [35] that destabilizes membranes containing
acidic phospholipids [36], we hypothesized that taurine could
inhibit FGF1 export in transgenic animals. Indeed, our recent
study [24] showed that in vitro stress-induced FGF1 export
correlates with phosphatidylserine externalization, and both
processes are inhibited by taurine. Therefore, we assessed the
effect of taurine on postischemic kidney repair and FGF1 export in
FGF1/Tek mice. The mice were administered water containing
10 mg/ml taurine from 48 h before to 21 days after kidney
ischemia, when the taurine-treated and control FGF1/Tek
animals were sacrificed to obtain kidneys and blood samples.
Taurine treatment resulted in a repression of FGF1 export to
circulation in most mice (Table 1). We also observed that while the
weight of postischemic kidneys in the six control animals varied
between 168 and 187 mg, in the four out of six mice treated with
Figure 2. Early postischemic response in FGF1/Tek and control animals. A. Expression of the kidney injury marker 1, Havcr1, in the
postischemic kidneys of FGF1/Tek and control WT FVB mice one day after ischemia. qRT-PCR results normalized to ß-actin expression. Kidneys of five
FGF1/Tek and five WT mice were studied. Mean and SEM are presented. B. PAS staining of the paraffin sections of postischemic and contralateral
kidneys of control WT FVB and FGF1/Tek mice. One day after ischemia, hematoxylin counterstaining. Bar –40 ˜ m C. Increase of the percentage of
tubules with enlarged lumen (lumen occupies more than J of tubule section) in postischemic kidneys comparatively to contralateral organs. Kidneys
of four FGF1/Tek and four WT mice were studied. Mean and SEM of fold increase are presented. D. Glomeruli diameters in postischemic and
contralateral kidneys. Kidneys of four FGF1/Tek and four WT mice were studied. Mean and SEM are presented.
doi:10.1371/journal.pone.0036485.g002
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animals, these four taurine treated mice contained no detectable
FGF1 in the vasculature (Table 1). Taurine did not inhibit FGF1
export in two animals, and these mice had low postischemic
kidney weights: 186 and 180 mg (Table 1). Thus, the rescuing
effect of taurine on postischemic kidney repair correlated with the
suppression of FGF1 export.
Besides having significantly increased weight (Figure 6A),
postischemic kidneys of mice with FGF1 release repressed by
taurine had less interstitial hyperplasia than the postischemic
kidneys of animals not treated with taurine (Figure 6B). The
postischemic/contralateral ratio of kidney tubule density in mice
with repressed FGF1 release (Figure 3C) was almost twice
higher than in FGF1/Tek animals untreated with taurine. In
addition, unlike taurine untreated animals, mice with FGF1
release repressed with taurine did not exhibit large groups of
macrophages and neutrophils in the interstitium of their
postischemic kidneys (Figure 3D).
7. Similar to FGF1/Tek Animals, FGF1/c-fms Transgenic
Mice Exhibit Attenuated Postischemic Kidney Repair
Like EC [37], macrophages and monocytes present a source of
nonclassically secreted FGF1 and FGF2 in the organism [10]. To
assess the effect of macrophage-derived FGF1 on postischemic
kidney repair, we produced mice with monocyte/macrophage
specific overexpression of FGF1. pTRE-Tight/FGF1 transgenic
mice were crossed with rtTA/c-fms transgenic animals [30] that
had been bred on an FVB background. Peritoneal macrophages
that were obtained from the bi-transgenic FGF1/c-fms mice
pretreated with doxycycline expressed FGF1:HA, while it was
undetectable in macrophages obtained form the animals that did
not receive doxycycline (Figure 7A). ELISA analysis demonstrated
Figure 3. Decrease of postischemic kidney size and loss of tubular epithelial structures in FGF1/Tek animals. A. Representative
contralateral and postischemic kidneys of FGF1/Tek and control FVB (WT) animals, 21 days after ischemia/reperfusion. B. Decrease of postischemic
kidneys weight (red) and increase of contralateral kidneys weight (blue) in FGF1/Tek mice compared to FVB mice (WT). Mean and SEM are presented.
C. Sections of contralateral (two top sections per slide) and postischemic (two bottom sections per slide) kidneys of FGF1/Tek and control mice. D.
Loss of tubular structures in a postischemic kidney of an FGF1/Tek mouse. Postischemic and contralateral kidneys of an FGF1/Tek and a control WT
mouse are presented. Hematoxylin/eosin stained paraffin sections. Bar 2120m. E. Postischemic/contralateral % ratio (mean and SEM) of kidney tubule
density in FGF1/Tek and WT mice. Numbers of epithelial tubular structures in ten610 objective field were counted in postischemic and contralateral
kidneys of four FGF1/Tek and four wild type mice.
doi:10.1371/journal.pone.0036485.g003
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the vasculature of FGF1/c-fms mice (Figure 7B). Thus, unlike
FGF1/Tek mice, the cell type-specific expression of FGF1 in
FGF1/c-fms animal depended on doxycycline stimulation. How-
ever, to equalize the mice for potential side effects of long-term
doxycycline treatment, we choose to treat experimental (FGF1/c-
fms) and control WT animals with doxycycline instead of
comparing doxycycline-treated and untreated FGF1/c-fms mice.
In unilateral kidney ischemia experiments, FGF1/c-fms and
control WT two-month-old males were fed with doxycycline-
containing water (660 mg/l), beginning 48 h before and up to day
21 after surgery. We found that like FGF1/Tek mice, FGF1/c-fms
animals displayed a significant decrease of the weight of
postischemic kidneys (Figure 7C,D) comparatively to WT animals.
In addition, when compared to control mice the postischemic
kidneys of FGF1/c-fms mice were characterized by enhanced
hyperplasia of interstitial cells and significantly stronger loss of
tubular structures (Figure 7E,F). Thus, similar to EC-derived,
monocyte/macrophage-derived FGF1 can attenuate the postis-
chemic kidney recovery.
Discussion
Mice transgenically expressing FGF1 in EC are, to our
knowledge, the first animal model used to study nonclassical
protein export, its regulation and biological effects in vivo. We
found that although FGF1/Tek mice displayed normal fertility,
development, and phenotype (including normal kidney histolo-
gy), they responded to ischemia/reperfusion by massive fibrosis.
It is interesting that while in absence of ischemia, FGF1/Tek
mice exhibited release of FGF1 to the circulation, it did not
result in kidney pathologies. It is possible that continuous tissue
stress following ischemic treatment stimulates FGF1 export from
the basal surface of EC, which causes lasting proliferative
stimulation of interstitial fibroblasts surrounding the capillaries.
Alternatively, ischemia may induce the leakiness of the
endothelial monolayer and thus diffusion of FGF1 released
from the apical surface of EC to the exposed areas of the basal
membrane. Tek (Tie2) promoter-driven expression is widely
used for targeting transgene products to EC, particularly in the
studies of the effects of FGF signaling in the cardiovascular
systems [38]. However, there have been reports that Tek is also
expressed in some subpopulations of macrophages [39].
Although our immunohistochemistry results show that EC is
the locale where FGF1 is expressed in FGF1/Tek mice, we
cannot exclude, that a portion of transgenic FGF1 could also be
derived from macrophages.
The presence of numerous proliferating cells in the interstitium
of postischemic kidneys of FGF1/Tek mice supports the hypoth-
esis that ischemia stimulates FGF1 export from EC to surrounding
structures. Recent work indicates that pericyte proliferation leads
to the characteristic interstitial expansion seen in fibrosis following
Figure 4. Fibrosis and cell proliferation in the postischemic kidneys of FGF1/Tek mice. Twenty-one days after ischemia, paraffin sections
of postischemic and contralateral kidneys of FGF1/Tek and control FVB mice. A. Trichrome staining. B. Sirius red staining for collagen. Polarization
microscopy. C. Immunoperoxidase staining for Ki-67, a marker of cell proliferation. In B and C, hematoxylin counterstaining was used. Bar in A –80 m.
Bars in B and C –40 m. D. Quantification of Sirius staining: % of kidney section area positive for Sirius Red (mean and SEM) is presented. Kidneys of four
FGF1/Tek and four WT mice were studied. E. Quantification of cell proliferation: % cells positive for Ki-67 (mean and SEM) is presented. Kidneys of four
FGF1/Tek and four WT mice were studied.
doi:10.1371/journal.pone.0036485.g004
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directly stimulate proliferation and migration of underlying
pericytes. Additionally, FGF1 released to the interstitium of
postischemic kidneys attracts neutrophils and macrophages that
secrete the proinflammatory or mitogenic proteins: IL1, TGFbeta,
ET-1, EGF, CTGF [41,42], potentially promoting fibrosis. Thus,
we propose that a complex and multifactorial cascade of events
may cause the massive fibrosis and dysfunction seen in kidneys of
mice with increased expression of nonclassically released FGF in
EC.
Interestingly, Gerber et al. [43] recently reported that the
knockout of FGFRL1, a decoy FGF receptor that binds the
excess of FGFs, results in premature termination of metanephric
kidney development, apparently because mesenchymo-epithelial
transformation required for differentiation of tubular structures
is inhibited by overabundant FGFs. The ubiquitous expression
of FGF1 and FGF2 in the adult organism can reflect their role
as latent stimulators of tissue repair, which become available
when tissue stress induces their export. However, an excess of
non-classically exported FGFs also can result in fibrosis and
Figure 5. Massive infiltration of neutrophils and macrophages in the postischemic kidneys of FGF1/Tek mice. Twenty-one days after
ischemia, paraffin sections of the postischemic and contralateral kidneys of FGF1/Tek and control FVB mice were stained using the
immunoperoxidase method for a neutrophil marker or F4/80, a macrophage marker. Hematoxylin counterstaining. Bar –40 ˜ m.
doi:10.1371/journal.pone.0036485.g005
Table 1. Effect of taurine treatment on FGF1 release and postischemic kidney weight in FGF1/Tek mice.
Mouse # Taurine treatment Contralateral kidney weight, mg Postischemic kidney weight, mg FGF1 blood content, ng/ml
1 2 242 174 5.32
2 2 201 168 1.52
3 2 233 187 3.66
4 2 203 184 2.38
5 2 250 182 4.75
6 2 296 171 4.27
1t + 231 217 0
2t + 240 201 0
3t + 210 201 0
4t + 229 203 0
5t + 225 186 6.61
6t + 304 180 0.86
FGF1/Tek mice were fed with water containing taurine (10 mg/ml) or taurine-free water from 2 days before to day 21 after ischemia/reperfusion, when they were
sacrificed. FGF1 content in the vasculature was determined by the ELISA method.
doi:10.1371/journal.pone.0036485.t001
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FGF1 and FGF2 significantly decreases chemically induced liver
fibrosis [44], while transgenic expression of FGF2 in cardiomy-
ocytes exacerbated myocardial injury [45]. In addition, it is
noteworthy that (i) genetically determined overexpression of
FGF1 in the mesangial cells of kidneys correlates with
hereditary hypertension [25]; (ii) FGF2 is implicated in
pulmonary hypertension [26], (iii) FGF1 released by EC is a
key stimulator of adipogenesis and thus can be involved in
obesity [27].
The emerging hypothesis about the pathological potential of
non-classically released FGFs, supported by the present work
underlines the importance of pharmacological regulation of
unconventional protein secretion. We found that taurine
inhibited FGF1 export in vivo and rescued kidney repair in
FGF1/Tek mice. The ability of taurine to suppress nonclassical
protein export based on membrane stabilization may partially
explain the beneficial effect of this small molecule in kidney
fibrosis and other inflammatory diseases [34,46,47,48].
In additional experiments using FGF1/c-fms mice, we found
that FGF1 derived from macrophages can also induce the
abnormal postischemic recovery of the kidney characterized by
the loss of tubular structures and hyperplasia of interstitial cells.
This effect is apparently due to the well-documented macrophage
Figure 6. Taurine inhibits FGF1 release in FGF1/Tek mice and rescues the postischemic kidney recovery. FGF1/Tek mice were fed with
water containing taurine (10 mg/ml) or taurine-free water from 2 days before to day 21 after ischemia/reperfusion, when they were sacrificed. FGF1
content in the vasculature was determined by the ELISA method (see Table 1). Four taurine-treated mice with inhibited FGF1 export and six untreated
mice were studied. A. Weights of contralateral and postischemic kidneys. Means and SEM are presented. B. Representative hematoxylin/eosin stained
paraffin sections of the postischemic and contralateral kidneys of a taurine-treated mouse and a control mouse. Bar 2120m. C. Postischemic/
contralateral % ratio (mean and SEM) of kidney tubule density in taurine-treated and untreated mice. Numbers of epithelial tubular structures in ten
610 objective fields were counted in postischemic and contralateral kidneys of four FGF1/Tek mice with taurine-inhibited FGF1 release and six FGF1/
Tek mice untreated with taurine. D. Paraffin sections of the postischemic and contralateral kidneys of taurine-treated and untreated mice were
stained using the immunoperoxidase method for a neutrophil marker or F4/80, a macrophage marker. Hematoxylin counterstaining. Bar –40 m.
doi:10.1371/journal.pone.0036485.g006
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e36485invasion into postischemic kidneys [49]. The ischemia efficiency
may vary from experiment to experiment and that explains the
difference in tubular structures loss in ischemic WT kidneys
between Figures 3E and 7F. However, the trend of drastic
exacerbation of postischemic damage in FGF1 transgenic animals
is maintained.
We anticipate that this first study of FGF1 export in vivo and its
effects on organ repair will increase the understanding of the
biological effects of non-classical protein secretion, elucidation of
its molecular mechanisms, and development of efficient methods
of its regulation.
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Figure 7. Decrease of organ size and loss of tubular structures in the postischemic kidneys of FGF1/c-fms transgenic mice. A.
Induction of FGF1/HA expression in the peritoneal macrophages of FGF1/c-fms transgenic mice. Forty-eight hours before being sacrificed, the
animals were intraperitoneally injected with 0.2 ml PBS containing 10 mg/ml doxycycline (right) or with doxycycline-free PBS (left). Macrophages were
obtained by flushing the peritoneal cavity with PBS, plated on coverslips in DMEM with 10% FBS, fixed 12 h after plating and stained using anti-HA
antibodies (green) and TOPRO3 (red). Confocal images are presented. Bar –20m. B. FGF1 release in the vasculature of FGF1/c-fms mice. The animals
were intraperitoneally injected with 0.2 ml PBS containing 10 mg/ml doxycycline (right) or with doxycycline-free PBS (left). Forty-eight hours later, the
animals were sacrificed. Their vasculatures were perfused with cold heparinized PBS, and the content of FGF1(ng/ml blood) was determined using an
FGF1 ELISA kit. C. Contralateral (top) and postischemic (bottom) kidneys of an FGF1/c-fms mouse, 21 days after ischemia/reperfusion, during which
period the animal was receiving water with doxycycline (660 mg/l). D. Sharp decrease of postischemic kidneys weight in FGF1/c-fms mice in
comparison with control FVB animals (WT). Means and SEM are presented. Both types of mice received doxycycline in water throughout the
experiment. E. Loss of tubular structures in the postischemic kidney of an FGF1/c-fms mouse. Representative hematoxylin and eosin stained paraffin
sections of postischemic and contralateral kidneys of FGF1/c-fms and wild WT mice. Bar –80 m.F. Postischemic/contralateral % ratio (mean and SEM)
of kidney tubule density in FGF1/c-fms and WT mice. Numbers of epithelial tubular structures in ten 610 objective fields were counted in
postischemic and contralateral kidneys of six FGF1/c-fms and nine WT mice.
doi:10.1371/journal.pone.0036485.g007
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